nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemcitabine—urinary bladder cancer—testicular cancer	0.251	0.418	CtDrD
Gemcitabine—kidney cancer—testicular cancer	0.178	0.296	CtDrD
Gemcitabine—lung cancer—testicular cancer	0.172	0.286	CtDrD
Gemcitabine—ABCC10—Etoposide—testicular cancer	0.0564	0.268	CbGbCtD
Gemcitabine—TYMS—Methotrexate—testicular cancer	0.0452	0.215	CbGbCtD
Gemcitabine—ABCC10—Doxorubicin—testicular cancer	0.0385	0.183	CbGbCtD
Gemcitabine—ABCC10—Methotrexate—testicular cancer	0.0372	0.177	CbGbCtD
Gemcitabine—ABCB1—Dactinomycin—testicular cancer	0.00931	0.0443	CbGbCtD
Gemcitabine—ABCB1—Vinblastine—testicular cancer	0.00583	0.0278	CbGbCtD
Gemcitabine—ABCB1—Cisplatin—testicular cancer	0.00535	0.0255	CbGbCtD
Gemcitabine—ABCB1—Etoposide—testicular cancer	0.00525	0.025	CbGbCtD
Gemcitabine—ABCB1—Doxorubicin—testicular cancer	0.00358	0.0171	CbGbCtD
Gemcitabine—ABCB1—Methotrexate—testicular cancer	0.00347	0.0165	CbGbCtD
Gemcitabine—POLE—embryo—testicular cancer	0.00159	0.041	CbGeAlD
Gemcitabine—TYMS—Trans-sulfuration and one carbon metabolism—DNMT3L—testicular cancer	0.00159	0.0492	CbGpPWpGaD
Gemcitabine—POLE—seminal vesicle—testicular cancer	0.00149	0.0385	CbGeAlD
Gemcitabine—POLD1—Global Genomic NER (GG-NER)—ERCC4—testicular cancer	0.00148	0.0458	CbGpPWpGaD
Gemcitabine—POLD1—gonad—testicular cancer	0.00144	0.0372	CbGeAlD
Gemcitabine—POLE—Global Genomic NER (GG-NER)—ERCC4—testicular cancer	0.00143	0.0442	CbGpPWpGaD
Gemcitabine—RRM2—embryo—testicular cancer	0.00131	0.0338	CbGeAlD
Gemcitabine—POLD1—Global Genomic NER (GG-NER)—ERCC1—testicular cancer	0.00129	0.04	CbGpPWpGaD
Gemcitabine—POLA1—seminal vesicle—testicular cancer	0.00129	0.0332	CbGeAlD
Gemcitabine—POLE—Global Genomic NER (GG-NER)—ERCC1—testicular cancer	0.00125	0.0386	CbGpPWpGaD
Gemcitabine—POLD1—Transcription-coupled NER (TC-NER)—ERCC4—testicular cancer	0.00118	0.0366	CbGpPWpGaD
Gemcitabine—SLC28A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00118	0.0364	CbGpPWpGaD
Gemcitabine—POLD1—female gonad—testicular cancer	0.00117	0.0303	CbGeAlD
Gemcitabine—CMPK1—gonad—testicular cancer	0.00115	0.0297	CbGeAlD
Gemcitabine—POLE—Transcription-coupled NER (TC-NER)—ERCC4—testicular cancer	0.00114	0.0353	CbGpPWpGaD
Gemcitabine—POLD1—Nucleotide Excision Repair—ERCC4—testicular cancer	0.00109	0.0336	CbGpPWpGaD
Gemcitabine—POLE—gonad—testicular cancer	0.00108	0.0278	CbGeAlD
Gemcitabine—SLC28A3—female gonad—testicular cancer	0.00108	0.0278	CbGeAlD
Gemcitabine—POLE—Nucleotide Excision Repair—ERCC4—testicular cancer	0.00105	0.0325	CbGpPWpGaD
Gemcitabine—POLD1—testis—testicular cancer	0.00104	0.0268	CbGeAlD
Gemcitabine—POLD1—Transcription-coupled NER (TC-NER)—ERCC1—testicular cancer	0.00103	0.032	CbGpPWpGaD
Gemcitabine—RRM1—seminal vesicle—testicular cancer	0.00102	0.0264	CbGeAlD
Gemcitabine—POLE—Transcription-coupled NER (TC-NER)—ERCC1—testicular cancer	0.000999	0.0309	CbGpPWpGaD
Gemcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00096	0.0297	CbGpPWpGaD
Gemcitabine—POLD1—Nucleotide Excision Repair—ERCC1—testicular cancer	0.000951	0.0294	CbGpPWpGaD
Gemcitabine—CMPK1—female gonad—testicular cancer	0.000937	0.0241	CbGeAlD
Gemcitabine—CDA—testis—testicular cancer	0.000935	0.0241	CbGeAlD
Gemcitabine—POLE—Nucleotide Excision Repair—ERCC1—testicular cancer	0.000918	0.0284	CbGpPWpGaD
Gemcitabine—SLC28A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000893	0.0276	CbGpPWpGaD
Gemcitabine—RRM2—gonad—testicular cancer	0.000889	0.0229	CbGeAlD
Gemcitabine—POLE—female gonad—testicular cancer	0.000878	0.0226	CbGeAlD
Gemcitabine—DCK—embryo—testicular cancer	0.000846	0.0218	CbGeAlD
Gemcitabine—CMPK1—testis—testicular cancer	0.000831	0.0214	CbGeAlD
Gemcitabine—DCK—seminal vesicle—testicular cancer	0.000794	0.0205	CbGeAlD
Gemcitabine—POLE—testis—testicular cancer	0.000778	0.0201	CbGeAlD
Gemcitabine—ABCC10—seminal vesicle—testicular cancer	0.000757	0.0195	CbGeAlD
Gemcitabine—POLA1—female gonad—testicular cancer	0.000757	0.0195	CbGeAlD
Gemcitabine—POLD1—lymph node—testicular cancer	0.000755	0.0195	CbGeAlD
Gemcitabine—RRM1—gonad—testicular cancer	0.000739	0.019	CbGeAlD
Gemcitabine—RRM2—female gonad—testicular cancer	0.000723	0.0186	CbGeAlD
Gemcitabine—CDA—lymph node—testicular cancer	0.000677	0.0175	CbGeAlD
Gemcitabine—POLA1—testis—testicular cancer	0.000671	0.0173	CbGeAlD
Gemcitabine—RRM2—Vinorelbine—Vinblastine—testicular cancer	0.00067	0.359	CbGdCrCtD
Gemcitabine—TYMS—gonad—testicular cancer	0.00067	0.0173	CbGeAlD
Gemcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000666	0.0206	CbGpPWpGaD
Gemcitabine—RRM2—testis—testicular cancer	0.000641	0.0165	CbGeAlD
Gemcitabine—SLC29A2—lymph node—testicular cancer	0.000633	0.0163	CbGeAlD
Gemcitabine—CMPK1—lymph node—testicular cancer	0.000602	0.0155	CbGeAlD
Gemcitabine—SLC29A1—gonad—testicular cancer	0.000601	0.0155	CbGeAlD
Gemcitabine—RRM1—female gonad—testicular cancer	0.0006	0.0155	CbGeAlD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000599	0.0185	CbGpPWpGaD
Gemcitabine—DCK—gonad—testicular cancer	0.000574	0.0148	CbGeAlD
Gemcitabine—POLD1—DNA Repair—ERCC4—testicular cancer	0.000567	0.0175	CbGpPWpGaD
Gemcitabine—POLE—lymph node—testicular cancer	0.000564	0.0145	CbGeAlD
Gemcitabine—POLE—DNA Repair—ERCC4—testicular cancer	0.000547	0.0169	CbGpPWpGaD
Gemcitabine—ABCC10—gonad—testicular cancer	0.000547	0.0141	CbGeAlD
Gemcitabine—TYMS—female gonad—testicular cancer	0.000544	0.014	CbGeAlD
Gemcitabine—RRM1—testis—testicular cancer	0.000533	0.0137	CbGeAlD
Gemcitabine—POLD1—DNA Repair—ERCC1—testicular cancer	0.000495	0.0153	CbGpPWpGaD
Gemcitabine—SLC29A1—female gonad—testicular cancer	0.000488	0.0126	CbGeAlD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000488	0.0151	CbGpPWpGaD
Gemcitabine—POLA1—lymph node—testicular cancer	0.000486	0.0125	CbGeAlD
Gemcitabine—TYMS—testis—testicular cancer	0.000483	0.0124	CbGeAlD
Gemcitabine—POLE—DNA Repair—ERCC1—testicular cancer	0.000478	0.0148	CbGpPWpGaD
Gemcitabine—DCK—female gonad—testicular cancer	0.000466	0.012	CbGeAlD
Gemcitabine—RRM2—lymph node—testicular cancer	0.000465	0.012	CbGeAlD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000463	0.0143	CbGpPWpGaD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000454	0.014	CbGpPWpGaD
Gemcitabine—ABCC10—female gonad—testicular cancer	0.000444	0.0115	CbGeAlD
Gemcitabine—SLC29A1—testis—testicular cancer	0.000433	0.0112	CbGeAlD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000427	0.0132	CbGpPWpGaD
Gemcitabine—POLD1—Telomere Maintenance—H2AFZ—testicular cancer	0.000414	0.0128	CbGpPWpGaD
Gemcitabine—DCK—testis—testicular cancer	0.000414	0.0107	CbGeAlD
Gemcitabine—POLE—Telomere Maintenance—H2AFZ—testicular cancer	0.0004	0.0124	CbGpPWpGaD
Gemcitabine—ABCC10—testis—testicular cancer	0.000394	0.0102	CbGeAlD
Gemcitabine—RRM1—lymph node—testicular cancer	0.000386	0.00995	CbGeAlD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000382	0.0118	CbGpPWpGaD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000366	0.0113	CbGpPWpGaD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000357	0.011	CbGpPWpGaD
Gemcitabine—TYMS—lymph node—testicular cancer	0.00035	0.00902	CbGeAlD
Gemcitabine—POLD1—Chromosome Maintenance—H2AFZ—testicular cancer	0.000345	0.0107	CbGpPWpGaD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000338	0.0105	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000338	0.0104	CbGpPWpGaD
Gemcitabine—POLE—Chromosome Maintenance—H2AFZ—testicular cancer	0.000333	0.0103	CbGpPWpGaD
Gemcitabine—SLC29A1—lymph node—testicular cancer	0.000314	0.00809	CbGeAlD
Gemcitabine—DCK—lymph node—testicular cancer	0.0003	0.00773	CbGeAlD
Gemcitabine—TYMS—Vinorelbine—Vinblastine—testicular cancer	0.000286	0.153	CbGdCrCtD
Gemcitabine—TYMS—Podofilox—Etoposide—testicular cancer	0.000286	0.153	CbGdCrCtD
Gemcitabine—ABCC10—lymph node—testicular cancer	0.000286	0.00736	CbGeAlD
Gemcitabine—POLA1—Telomere Maintenance—H2AFZ—testicular cancer	0.000285	0.0088	CbGpPWpGaD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000261	0.00807	CbGpPWpGaD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.00025	0.00773	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000246	0.00759	CbGpPWpGaD
Gemcitabine—TYMS—Vincristine—Vinblastine—testicular cancer	0.000245	0.131	CbGdCrCtD
Gemcitabine—POLA1—Chromosome Maintenance—H2AFZ—testicular cancer	0.000237	0.00733	CbGpPWpGaD
Gemcitabine—ABCB1—embryo—testicular cancer	0.000233	0.006	CbGeAlD
Gemcitabine—ABCB1—seminal vesicle—testicular cancer	0.000218	0.00563	CbGeAlD
Gemcitabine—DCK—Doxorubicin—Epirubicin—testicular cancer	0.000198	0.106	CbGdCrCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00019	0.00588	CbGpPWpGaD
Gemcitabine—DCK—Epirubicin—Doxorubicin—testicular cancer	0.000183	0.0981	CbGdCrCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000182	0.00564	CbGpPWpGaD
Gemcitabine—POLE—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.000181	0.0056	CbGpPWpGaD
Gemcitabine—ABCB1—gonad—testicular cancer	0.000158	0.00407	CbGeAlD
Gemcitabine—RRM2—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000141	0.00437	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.00014	0.00434	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000138	0.00428	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000136	0.00419	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—HPGDS—testicular cancer	0.000134	0.00415	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000133	0.0041	CbGpPWpGaD
Gemcitabine—POLA1—Mitotic M-M/G1 phases—MAD1L1—testicular cancer	0.000129	0.00399	CbGpPWpGaD
Gemcitabine—ABCB1—female gonad—testicular cancer	0.000128	0.00331	CbGeAlD
Gemcitabine—POLE—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000126	0.00391	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—MAD1L1—testicular cancer	0.000126	0.0039	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—MAD1L1—testicular cancer	0.000126	0.00388	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—MAD1L1—testicular cancer	0.000121	0.00375	CbGpPWpGaD
Gemcitabine—ABCB1—testis—testicular cancer	0.000114	0.00293	CbGeAlD
Gemcitabine—RRM2—Cell Cycle, Mitotic—H2AFZ—testicular cancer	9.85e-05	0.00304	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	9.79e-05	0.00303	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—STK11—testicular cancer	9.76e-05	0.00302	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—MAD1L1—testicular cancer	9.66e-05	0.00299	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—H2AFZ—testicular cancer	9.45e-05	0.00292	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—MAD1L1—testicular cancer	9.26e-05	0.00286	CbGpPWpGaD
Gemcitabine—POLA1—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	9.01e-05	0.00278	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—H2AFZ—testicular cancer	8.81e-05	0.00272	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—H2AFZ—testicular cancer	8.75e-05	0.0027	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—MAD1L1—testicular cancer	8.64e-05	0.00267	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—H2AFZ—testicular cancer	8.45e-05	0.00261	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—HPGDS—testicular cancer	8.3e-05	0.00256	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—MAD1L1—testicular cancer	8.28e-05	0.00256	CbGpPWpGaD
Gemcitabine—ABCB1—lymph node—testicular cancer	8.25e-05	0.00213	CbGeAlD
Gemcitabine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	7.67e-05	0.00237	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	6.74e-05	0.00208	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—H2AFZ—testicular cancer	6.45e-05	0.00199	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—HPGDS—testicular cancer	6.29e-05	0.00194	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.16e-05	0.0019	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—STK11—testicular cancer	6.03e-05	0.00186	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—H2AFZ—testicular cancer	6.02e-05	0.00186	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—H2AFZ—testicular cancer	5.77e-05	0.00178	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.63e-05	0.00174	CbGpPWpGaD
Gemcitabine—Hypokalaemia—Doxorubicin—testicular cancer	5.33e-05	0.000458	CcSEcCtD
Gemcitabine—Anorexia—Etoposide—testicular cancer	5.29e-05	0.000454	CcSEcCtD
Gemcitabine—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	5.27e-05	0.000453	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	5.27e-05	0.000453	CcSEcCtD
Gemcitabine—Decreased appetite—Cisplatin—testicular cancer	5.27e-05	0.000452	CcSEcCtD
Gemcitabine—Diarrhoea—Dactinomycin—testicular cancer	5.25e-05	0.000451	CcSEcCtD
Gemcitabine—Pneumonia—Methotrexate—testicular cancer	5.24e-05	0.00045	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Cisplatin—testicular cancer	5.23e-05	0.000449	CcSEcCtD
Gemcitabine—Vomiting—Bleomycin—testicular cancer	5.23e-05	0.000449	CcSEcCtD
Gemcitabine—Pancytopenia—Epirubicin—testicular cancer	5.2e-05	0.000446	CcSEcCtD
Gemcitabine—Hypotension—Etoposide—testicular cancer	5.19e-05	0.000445	CcSEcCtD
Gemcitabine—Rash—Bleomycin—testicular cancer	5.19e-05	0.000445	CcSEcCtD
Gemcitabine—Pain—Cisplatin—testicular cancer	5.18e-05	0.000445	CcSEcCtD
Gemcitabine—Dermatitis—Bleomycin—testicular cancer	5.18e-05	0.000445	CcSEcCtD
Gemcitabine—RRM2—Metabolism—HPGDS—testicular cancer	5.18e-05	0.0016	CbGpPWpGaD
Gemcitabine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	5.17e-05	0.000444	CcSEcCtD
Gemcitabine—Alanine aminotransferase increased—Doxorubicin—testicular cancer	5.17e-05	0.000444	CcSEcCtD
Gemcitabine—POLD1—Metabolism—HPGDS—testicular cancer	5.15e-05	0.00159	CbGpPWpGaD
Gemcitabine—Renal failure—Methotrexate—testicular cancer	5.12e-05	0.00044	CcSEcCtD
Gemcitabine—Neutropenia—Epirubicin—testicular cancer	5.12e-05	0.000439	CcSEcCtD
Gemcitabine—Stomatitis—Methotrexate—testicular cancer	5.08e-05	0.000436	CcSEcCtD
Gemcitabine—Influenza—Doxorubicin—testicular cancer	5.06e-05	0.000435	CcSEcCtD
Gemcitabine—Asthenia—Ifosfamide—testicular cancer	5.04e-05	0.000433	CcSEcCtD
Gemcitabine—Sweating—Methotrexate—testicular cancer	5e-05	0.000429	CcSEcCtD
Gemcitabine—Feeling abnormal—Cisplatin—testicular cancer	4.99e-05	0.000429	CcSEcCtD
Gemcitabine—Paraesthesia—Etoposide—testicular cancer	4.98e-05	0.000428	CcSEcCtD
Gemcitabine—Pruritus—Ifosfamide—testicular cancer	4.97e-05	0.000427	CcSEcCtD
Gemcitabine—Haematuria—Methotrexate—testicular cancer	4.97e-05	0.000427	CcSEcCtD
Gemcitabine—Dyspnoea—Etoposide—testicular cancer	4.95e-05	0.000425	CcSEcCtD
Gemcitabine—Hyperglycaemia—Epirubicin—testicular cancer	4.94e-05	0.000424	CcSEcCtD
Gemcitabine—Somnolence—Etoposide—testicular cancer	4.93e-05	0.000424	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Methotrexate—testicular cancer	4.93e-05	0.000423	CcSEcCtD
Gemcitabine—Pneumonia—Epirubicin—testicular cancer	4.91e-05	0.000421	CcSEcCtD
Gemcitabine—Nausea—Bleomycin—testicular cancer	4.88e-05	0.00042	CcSEcCtD
Gemcitabine—Vomiting—Dactinomycin—testicular cancer	4.88e-05	0.000419	CcSEcCtD
Gemcitabine—Agranulocytosis—Methotrexate—testicular cancer	4.87e-05	0.000418	CcSEcCtD
Gemcitabine—DCK—Metabolism—HPGDS—testicular cancer	4.84e-05	0.0015	CbGpPWpGaD
Gemcitabine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	4.84e-05	0.000415	CcSEcCtD
Gemcitabine—Rash—Dactinomycin—testicular cancer	4.84e-05	0.000415	CcSEcCtD
Gemcitabine—Decreased appetite—Etoposide—testicular cancer	4.83e-05	0.000414	CcSEcCtD
Gemcitabine—Diarrhoea—Ifosfamide—testicular cancer	4.81e-05	0.000413	CcSEcCtD
Gemcitabine—Pancytopenia—Doxorubicin—testicular cancer	4.81e-05	0.000413	CcSEcCtD
Gemcitabine—Renal failure—Epirubicin—testicular cancer	4.8e-05	0.000412	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Etoposide—testicular cancer	4.79e-05	0.000412	CcSEcCtD
Gemcitabine—Body temperature increased—Cisplatin—testicular cancer	4.79e-05	0.000411	CcSEcCtD
Gemcitabine—Fatigue—Etoposide—testicular cancer	4.79e-05	0.000411	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Epirubicin—testicular cancer	4.78e-05	0.000411	CcSEcCtD
Gemcitabine—Stomatitis—Epirubicin—testicular cancer	4.76e-05	0.000408	CcSEcCtD
Gemcitabine—Constipation—Etoposide—testicular cancer	4.75e-05	0.000408	CcSEcCtD
Gemcitabine—Pain—Etoposide—testicular cancer	4.75e-05	0.000408	CcSEcCtD
Gemcitabine—Neutropenia—Doxorubicin—testicular cancer	4.73e-05	0.000407	CcSEcCtD
Gemcitabine—Haemoglobin—Methotrexate—testicular cancer	4.7e-05	0.000404	CcSEcCtD
Gemcitabine—Haemorrhage—Methotrexate—testicular cancer	4.68e-05	0.000402	CcSEcCtD
Gemcitabine—Sweating—Epirubicin—testicular cancer	4.68e-05	0.000402	CcSEcCtD
Gemcitabine—Haematuria—Epirubicin—testicular cancer	4.65e-05	0.000399	CcSEcCtD
Gemcitabine—Pharyngitis—Methotrexate—testicular cancer	4.64e-05	0.000399	CcSEcCtD
Gemcitabine—Urinary tract disorder—Methotrexate—testicular cancer	4.62e-05	0.000397	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Epirubicin—testicular cancer	4.61e-05	0.000396	CcSEcCtD
Gemcitabine—Urethral disorder—Methotrexate—testicular cancer	4.59e-05	0.000394	CcSEcCtD
Gemcitabine—Feeling abnormal—Etoposide—testicular cancer	4.57e-05	0.000393	CcSEcCtD
Gemcitabine—RRM1—Metabolism—STK11—testicular cancer	4.57e-05	0.00141	CbGpPWpGaD
Gemcitabine—Hyperglycaemia—Doxorubicin—testicular cancer	4.57e-05	0.000392	CcSEcCtD
Gemcitabine—Nausea—Dactinomycin—testicular cancer	4.56e-05	0.000391	CcSEcCtD
Gemcitabine—Agranulocytosis—Epirubicin—testicular cancer	4.55e-05	0.000391	CcSEcCtD
Gemcitabine—Pneumonia—Doxorubicin—testicular cancer	4.54e-05	0.00039	CcSEcCtD
Gemcitabine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	4.48e-05	0.000384	CcSEcCtD
Gemcitabine—Vomiting—Ifosfamide—testicular cancer	4.47e-05	0.000384	CcSEcCtD
Gemcitabine—Renal failure—Doxorubicin—testicular cancer	4.44e-05	0.000381	CcSEcCtD
Gemcitabine—Rash—Ifosfamide—testicular cancer	4.43e-05	0.000381	CcSEcCtD
Gemcitabine—Dermatitis—Ifosfamide—testicular cancer	4.43e-05	0.00038	CcSEcCtD
Gemcitabine—Erythema multiforme—Methotrexate—testicular cancer	4.43e-05	0.00038	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Doxorubicin—testicular cancer	4.42e-05	0.00038	CcSEcCtD
Gemcitabine—Haemoglobin—Epirubicin—testicular cancer	4.4e-05	0.000378	CcSEcCtD
Gemcitabine—Stomatitis—Doxorubicin—testicular cancer	4.4e-05	0.000378	CcSEcCtD
Gemcitabine—Rhinitis—Epirubicin—testicular cancer	4.39e-05	0.000377	CcSEcCtD
Gemcitabine—Body temperature increased—Etoposide—testicular cancer	4.39e-05	0.000377	CcSEcCtD
Gemcitabine—Haemorrhage—Epirubicin—testicular cancer	4.38e-05	0.000376	CcSEcCtD
Gemcitabine—Asthenia—Cisplatin—testicular cancer	4.35e-05	0.000373	CcSEcCtD
Gemcitabine—Pharyngitis—Epirubicin—testicular cancer	4.35e-05	0.000373	CcSEcCtD
Gemcitabine—Cardiac disorder—Methotrexate—testicular cancer	4.34e-05	0.000373	CcSEcCtD
Gemcitabine—Sweating—Doxorubicin—testicular cancer	4.33e-05	0.000372	CcSEcCtD
Gemcitabine—Urinary tract disorder—Epirubicin—testicular cancer	4.33e-05	0.000371	CcSEcCtD
Gemcitabine—Oedema peripheral—Epirubicin—testicular cancer	4.31e-05	0.000371	CcSEcCtD
Gemcitabine—Haematuria—Doxorubicin—testicular cancer	4.3e-05	0.00037	CcSEcCtD
Gemcitabine—Connective tissue disorder—Epirubicin—testicular cancer	4.3e-05	0.00037	CcSEcCtD
Gemcitabine—Urethral disorder—Epirubicin—testicular cancer	4.29e-05	0.000369	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Doxorubicin—testicular cancer	4.27e-05	0.000367	CcSEcCtD
Gemcitabine—Angiopathy—Methotrexate—testicular cancer	4.25e-05	0.000365	CcSEcCtD
Gemcitabine—Immune system disorder—Methotrexate—testicular cancer	4.23e-05	0.000363	CcSEcCtD
Gemcitabine—Mediastinal disorder—Methotrexate—testicular cancer	4.22e-05	0.000362	CcSEcCtD
Gemcitabine—Agranulocytosis—Doxorubicin—testicular cancer	4.21e-05	0.000362	CcSEcCtD
Gemcitabine—Chills—Methotrexate—testicular cancer	4.2e-05	0.000361	CcSEcCtD
Gemcitabine—Nausea—Ifosfamide—testicular cancer	4.17e-05	0.000359	CcSEcCtD
Gemcitabine—Diarrhoea—Cisplatin—testicular cancer	4.15e-05	0.000356	CcSEcCtD
Gemcitabine—Erythema multiforme—Epirubicin—testicular cancer	4.14e-05	0.000356	CcSEcCtD
Gemcitabine—Alopecia—Methotrexate—testicular cancer	4.14e-05	0.000355	CcSEcCtD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	4.09e-05	0.00126	CbGpPWpGaD
Gemcitabine—Erythema—Methotrexate—testicular cancer	4.07e-05	0.00035	CcSEcCtD
Gemcitabine—Haemoglobin—Doxorubicin—testicular cancer	4.07e-05	0.00035	CcSEcCtD
Gemcitabine—Cardiac disorder—Epirubicin—testicular cancer	4.06e-05	0.000349	CcSEcCtD
Gemcitabine—Rhinitis—Doxorubicin—testicular cancer	4.06e-05	0.000349	CcSEcCtD
Gemcitabine—Haemorrhage—Doxorubicin—testicular cancer	4.05e-05	0.000348	CcSEcCtD
Gemcitabine—Pharyngitis—Doxorubicin—testicular cancer	4.02e-05	0.000345	CcSEcCtD
Gemcitabine—Urinary tract disorder—Doxorubicin—testicular cancer	4e-05	0.000344	CcSEcCtD
Gemcitabine—Oedema peripheral—Doxorubicin—testicular cancer	3.99e-05	0.000343	CcSEcCtD
Gemcitabine—Asthenia—Etoposide—testicular cancer	3.98e-05	0.000342	CcSEcCtD
Gemcitabine—Connective tissue disorder—Doxorubicin—testicular cancer	3.98e-05	0.000342	CcSEcCtD
Gemcitabine—Angiopathy—Epirubicin—testicular cancer	3.97e-05	0.000341	CcSEcCtD
Gemcitabine—Urethral disorder—Doxorubicin—testicular cancer	3.97e-05	0.000341	CcSEcCtD
Gemcitabine—Immune system disorder—Epirubicin—testicular cancer	3.96e-05	0.00034	CcSEcCtD
Gemcitabine—Mediastinal disorder—Epirubicin—testicular cancer	3.95e-05	0.000339	CcSEcCtD
Gemcitabine—Back pain—Methotrexate—testicular cancer	3.94e-05	0.000338	CcSEcCtD
Gemcitabine—Chills—Epirubicin—testicular cancer	3.93e-05	0.000337	CcSEcCtD
Gemcitabine—Pruritus—Etoposide—testicular cancer	3.93e-05	0.000337	CcSEcCtD
Gemcitabine—Arrhythmia—Epirubicin—testicular cancer	3.91e-05	0.000336	CcSEcCtD
Gemcitabine—Alopecia—Epirubicin—testicular cancer	3.87e-05	0.000332	CcSEcCtD
Gemcitabine—Vomiting—Cisplatin—testicular cancer	3.85e-05	0.000331	CcSEcCtD
Gemcitabine—Erythema multiforme—Doxorubicin—testicular cancer	3.83e-05	0.000329	CcSEcCtD
Gemcitabine—Rash—Cisplatin—testicular cancer	3.82e-05	0.000328	CcSEcCtD
Gemcitabine—Dermatitis—Cisplatin—testicular cancer	3.82e-05	0.000328	CcSEcCtD
Gemcitabine—Erythema—Epirubicin—testicular cancer	3.81e-05	0.000327	CcSEcCtD
Gemcitabine—Diarrhoea—Etoposide—testicular cancer	3.8e-05	0.000326	CcSEcCtD
Gemcitabine—Ill-defined disorder—Methotrexate—testicular cancer	3.78e-05	0.000325	CcSEcCtD
Gemcitabine—Anaemia—Methotrexate—testicular cancer	3.77e-05	0.000323	CcSEcCtD
Gemcitabine—RRM2—Metabolism—STK11—testicular cancer	3.76e-05	0.00116	CbGpPWpGaD
Gemcitabine—Cardiac disorder—Doxorubicin—testicular cancer	3.76e-05	0.000323	CcSEcCtD
Gemcitabine—POLD1—Metabolism—STK11—testicular cancer	3.74e-05	0.00116	CbGpPWpGaD
Gemcitabine—Back pain—Epirubicin—testicular cancer	3.69e-05	0.000317	CcSEcCtD
Gemcitabine—Angiopathy—Doxorubicin—testicular cancer	3.68e-05	0.000316	CcSEcCtD
Gemcitabine—Malaise—Methotrexate—testicular cancer	3.67e-05	0.000316	CcSEcCtD
Gemcitabine—Immune system disorder—Doxorubicin—testicular cancer	3.66e-05	0.000314	CcSEcCtD
Gemcitabine—Mediastinal disorder—Doxorubicin—testicular cancer	3.65e-05	0.000314	CcSEcCtD
Gemcitabine—Leukopenia—Methotrexate—testicular cancer	3.65e-05	0.000313	CcSEcCtD
Gemcitabine—Chills—Doxorubicin—testicular cancer	3.64e-05	0.000312	CcSEcCtD
Gemcitabine—Arrhythmia—Doxorubicin—testicular cancer	3.62e-05	0.000311	CcSEcCtD
Gemcitabine—Nausea—Cisplatin—testicular cancer	3.6e-05	0.000309	CcSEcCtD
Gemcitabine—Alopecia—Doxorubicin—testicular cancer	3.58e-05	0.000308	CcSEcCtD
Gemcitabine—Cough—Methotrexate—testicular cancer	3.56e-05	0.000305	CcSEcCtD
Gemcitabine—Ill-defined disorder—Epirubicin—testicular cancer	3.54e-05	0.000304	CcSEcCtD
Gemcitabine—Vomiting—Etoposide—testicular cancer	3.53e-05	0.000303	CcSEcCtD
Gemcitabine—Erythema—Doxorubicin—testicular cancer	3.53e-05	0.000303	CcSEcCtD
Gemcitabine—Anaemia—Epirubicin—testicular cancer	3.52e-05	0.000303	CcSEcCtD
Gemcitabine—DCK—Metabolism—STK11—testicular cancer	3.52e-05	0.00109	CbGpPWpGaD
Gemcitabine—Rash—Etoposide—testicular cancer	3.5e-05	0.000301	CcSEcCtD
Gemcitabine—Dermatitis—Etoposide—testicular cancer	3.5e-05	0.0003	CcSEcCtD
Gemcitabine—Headache—Etoposide—testicular cancer	3.48e-05	0.000299	CcSEcCtD
Gemcitabine—Myalgia—Methotrexate—testicular cancer	3.47e-05	0.000298	CcSEcCtD
Gemcitabine—Chest pain—Methotrexate—testicular cancer	3.47e-05	0.000298	CcSEcCtD
Gemcitabine—Arthralgia—Methotrexate—testicular cancer	3.47e-05	0.000298	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	3.44e-05	0.000296	CcSEcCtD
Gemcitabine—Malaise—Epirubicin—testicular cancer	3.44e-05	0.000295	CcSEcCtD
Gemcitabine—Discomfort—Methotrexate—testicular cancer	3.43e-05	0.000294	CcSEcCtD
Gemcitabine—Leukopenia—Epirubicin—testicular cancer	3.41e-05	0.000293	CcSEcCtD
Gemcitabine—Back pain—Doxorubicin—testicular cancer	3.41e-05	0.000293	CcSEcCtD
Gemcitabine—TYMS—Metabolism—HPGDS—testicular cancer	3.39e-05	0.00105	CbGpPWpGaD
Gemcitabine—Cough—Epirubicin—testicular cancer	3.33e-05	0.000286	CcSEcCtD
Gemcitabine—Anaphylactic shock—Methotrexate—testicular cancer	3.32e-05	0.000286	CcSEcCtD
Gemcitabine—Infection—Methotrexate—testicular cancer	3.3e-05	0.000284	CcSEcCtD
Gemcitabine—Nausea—Etoposide—testicular cancer	3.3e-05	0.000283	CcSEcCtD
Gemcitabine—Hypertension—Epirubicin—testicular cancer	3.29e-05	0.000283	CcSEcCtD
Gemcitabine—Ill-defined disorder—Doxorubicin—testicular cancer	3.27e-05	0.000281	CcSEcCtD
Gemcitabine—Nervous system disorder—Methotrexate—testicular cancer	3.26e-05	0.00028	CcSEcCtD
Gemcitabine—Anaemia—Doxorubicin—testicular cancer	3.26e-05	0.00028	CcSEcCtD
Gemcitabine—Thrombocytopenia—Methotrexate—testicular cancer	3.26e-05	0.00028	CcSEcCtD
Gemcitabine—Chest pain—Epirubicin—testicular cancer	3.25e-05	0.000279	CcSEcCtD
Gemcitabine—Myalgia—Epirubicin—testicular cancer	3.25e-05	0.000279	CcSEcCtD
Gemcitabine—Arthralgia—Epirubicin—testicular cancer	3.25e-05	0.000279	CcSEcCtD
Gemcitabine—Skin disorder—Methotrexate—testicular cancer	3.23e-05	0.000277	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.22e-05	0.000277	CcSEcCtD
Gemcitabine—Hyperhidrosis—Methotrexate—testicular cancer	3.21e-05	0.000276	CcSEcCtD
Gemcitabine—Discomfort—Epirubicin—testicular cancer	3.21e-05	0.000275	CcSEcCtD
Gemcitabine—Malaise—Doxorubicin—testicular cancer	3.18e-05	0.000273	CcSEcCtD
Gemcitabine—Anorexia—Methotrexate—testicular cancer	3.17e-05	0.000272	CcSEcCtD
Gemcitabine—Leukopenia—Doxorubicin—testicular cancer	3.16e-05	0.000271	CcSEcCtD
Gemcitabine—Anaphylactic shock—Epirubicin—testicular cancer	3.11e-05	0.000267	CcSEcCtD
Gemcitabine—Oedema—Epirubicin—testicular cancer	3.11e-05	0.000267	CcSEcCtD
Gemcitabine—Hypotension—Methotrexate—testicular cancer	3.11e-05	0.000267	CcSEcCtD
Gemcitabine—Infection—Epirubicin—testicular cancer	3.09e-05	0.000265	CcSEcCtD
Gemcitabine—Cough—Doxorubicin—testicular cancer	3.08e-05	0.000264	CcSEcCtD
Gemcitabine—Nervous system disorder—Epirubicin—testicular cancer	3.05e-05	0.000262	CcSEcCtD
Gemcitabine—Thrombocytopenia—Epirubicin—testicular cancer	3.05e-05	0.000262	CcSEcCtD
Gemcitabine—Hypertension—Doxorubicin—testicular cancer	3.05e-05	0.000262	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Methotrexate—testicular cancer	3.03e-05	0.00026	CcSEcCtD
Gemcitabine—Skin disorder—Epirubicin—testicular cancer	3.02e-05	0.00026	CcSEcCtD
Gemcitabine—Hyperhidrosis—Epirubicin—testicular cancer	3.01e-05	0.000258	CcSEcCtD
Gemcitabine—Insomnia—Methotrexate—testicular cancer	3.01e-05	0.000258	CcSEcCtD
Gemcitabine—Arthralgia—Doxorubicin—testicular cancer	3e-05	0.000258	CcSEcCtD
Gemcitabine—Myalgia—Doxorubicin—testicular cancer	3e-05	0.000258	CcSEcCtD
Gemcitabine—Chest pain—Doxorubicin—testicular cancer	3e-05	0.000258	CcSEcCtD
Gemcitabine—Paraesthesia—Methotrexate—testicular cancer	2.99e-05	0.000256	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.98e-05	0.000256	CcSEcCtD
Gemcitabine—Discomfort—Doxorubicin—testicular cancer	2.97e-05	0.000255	CcSEcCtD
Gemcitabine—Anorexia—Epirubicin—testicular cancer	2.97e-05	0.000255	CcSEcCtD
Gemcitabine—Dyspnoea—Methotrexate—testicular cancer	2.96e-05	0.000255	CcSEcCtD
Gemcitabine—Somnolence—Methotrexate—testicular cancer	2.96e-05	0.000254	CcSEcCtD
Gemcitabine—Hypotension—Epirubicin—testicular cancer	2.91e-05	0.00025	CcSEcCtD
Gemcitabine—Decreased appetite—Methotrexate—testicular cancer	2.89e-05	0.000248	CcSEcCtD
Gemcitabine—Oedema—Doxorubicin—testicular cancer	2.88e-05	0.000247	CcSEcCtD
Gemcitabine—Anaphylactic shock—Doxorubicin—testicular cancer	2.88e-05	0.000247	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Methotrexate—testicular cancer	2.87e-05	0.000247	CcSEcCtD
Gemcitabine—Fatigue—Methotrexate—testicular cancer	2.87e-05	0.000246	CcSEcCtD
Gemcitabine—Infection—Doxorubicin—testicular cancer	2.86e-05	0.000246	CcSEcCtD
Gemcitabine—Pain—Methotrexate—testicular cancer	2.84e-05	0.000244	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.83e-05	0.000243	CcSEcCtD
Gemcitabine—Nervous system disorder—Doxorubicin—testicular cancer	2.82e-05	0.000242	CcSEcCtD
Gemcitabine—Thrombocytopenia—Doxorubicin—testicular cancer	2.82e-05	0.000242	CcSEcCtD
Gemcitabine—Insomnia—Epirubicin—testicular cancer	2.81e-05	0.000242	CcSEcCtD
Gemcitabine—Skin disorder—Doxorubicin—testicular cancer	2.8e-05	0.00024	CcSEcCtD
Gemcitabine—Paraesthesia—Epirubicin—testicular cancer	2.79e-05	0.00024	CcSEcCtD
Gemcitabine—Hyperhidrosis—Doxorubicin—testicular cancer	2.78e-05	0.000239	CcSEcCtD
Gemcitabine—Dyspnoea—Epirubicin—testicular cancer	2.77e-05	0.000238	CcSEcCtD
Gemcitabine—Somnolence—Epirubicin—testicular cancer	2.77e-05	0.000238	CcSEcCtD
Gemcitabine—Anorexia—Doxorubicin—testicular cancer	2.74e-05	0.000236	CcSEcCtD
Gemcitabine—Feeling abnormal—Methotrexate—testicular cancer	2.74e-05	0.000235	CcSEcCtD
Gemcitabine—Decreased appetite—Epirubicin—testicular cancer	2.7e-05	0.000232	CcSEcCtD
Gemcitabine—Hypotension—Doxorubicin—testicular cancer	2.69e-05	0.000231	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Epirubicin—testicular cancer	2.69e-05	0.000231	CcSEcCtD
Gemcitabine—Fatigue—Epirubicin—testicular cancer	2.68e-05	0.00023	CcSEcCtD
Gemcitabine—Constipation—Epirubicin—testicular cancer	2.66e-05	0.000229	CcSEcCtD
Gemcitabine—Pain—Epirubicin—testicular cancer	2.66e-05	0.000229	CcSEcCtD
Gemcitabine—Body temperature increased—Methotrexate—testicular cancer	2.63e-05	0.000226	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.62e-05	0.000225	CcSEcCtD
Gemcitabine—Insomnia—Doxorubicin—testicular cancer	2.6e-05	0.000224	CcSEcCtD
Gemcitabine—Paraesthesia—Doxorubicin—testicular cancer	2.59e-05	0.000222	CcSEcCtD
Gemcitabine—Dyspnoea—Doxorubicin—testicular cancer	2.57e-05	0.00022	CcSEcCtD
Gemcitabine—Feeling abnormal—Epirubicin—testicular cancer	2.56e-05	0.00022	CcSEcCtD
Gemcitabine—Somnolence—Doxorubicin—testicular cancer	2.56e-05	0.00022	CcSEcCtD
Gemcitabine—Decreased appetite—Doxorubicin—testicular cancer	2.5e-05	0.000215	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.49e-05	0.000213	CcSEcCtD
Gemcitabine—Fatigue—Doxorubicin—testicular cancer	2.48e-05	0.000213	CcSEcCtD
Gemcitabine—TYMS—Metabolism—STK11—testicular cancer	2.46e-05	0.000762	CbGpPWpGaD
Gemcitabine—Pain—Doxorubicin—testicular cancer	2.46e-05	0.000211	CcSEcCtD
Gemcitabine—Constipation—Doxorubicin—testicular cancer	2.46e-05	0.000211	CcSEcCtD
Gemcitabine—Body temperature increased—Epirubicin—testicular cancer	2.46e-05	0.000211	CcSEcCtD
Gemcitabine—Asthenia—Methotrexate—testicular cancer	2.39e-05	0.000205	CcSEcCtD
Gemcitabine—Feeling abnormal—Doxorubicin—testicular cancer	2.37e-05	0.000204	CcSEcCtD
Gemcitabine—Pruritus—Methotrexate—testicular cancer	2.35e-05	0.000202	CcSEcCtD
Gemcitabine—Body temperature increased—Doxorubicin—testicular cancer	2.28e-05	0.000195	CcSEcCtD
Gemcitabine—Diarrhoea—Methotrexate—testicular cancer	2.27e-05	0.000195	CcSEcCtD
Gemcitabine—Asthenia—Epirubicin—testicular cancer	2.23e-05	0.000192	CcSEcCtD
Gemcitabine—Pruritus—Epirubicin—testicular cancer	2.2e-05	0.000189	CcSEcCtD
Gemcitabine—Diarrhoea—Epirubicin—testicular cancer	2.13e-05	0.000183	CcSEcCtD
Gemcitabine—Vomiting—Methotrexate—testicular cancer	2.11e-05	0.000182	CcSEcCtD
Gemcitabine—Rash—Methotrexate—testicular cancer	2.1e-05	0.00018	CcSEcCtD
Gemcitabine—Dermatitis—Methotrexate—testicular cancer	2.09e-05	0.00018	CcSEcCtD
Gemcitabine—Headache—Methotrexate—testicular cancer	2.08e-05	0.000179	CcSEcCtD
Gemcitabine—Asthenia—Doxorubicin—testicular cancer	2.07e-05	0.000177	CcSEcCtD
Gemcitabine—Pruritus—Doxorubicin—testicular cancer	2.04e-05	0.000175	CcSEcCtD
Gemcitabine—Vomiting—Epirubicin—testicular cancer	1.98e-05	0.00017	CcSEcCtD
Gemcitabine—Nausea—Methotrexate—testicular cancer	1.97e-05	0.00017	CcSEcCtD
Gemcitabine—Diarrhoea—Doxorubicin—testicular cancer	1.97e-05	0.000169	CcSEcCtD
Gemcitabine—Rash—Epirubicin—testicular cancer	1.96e-05	0.000168	CcSEcCtD
Gemcitabine—Dermatitis—Epirubicin—testicular cancer	1.96e-05	0.000168	CcSEcCtD
Gemcitabine—Headache—Epirubicin—testicular cancer	1.95e-05	0.000167	CcSEcCtD
Gemcitabine—Nausea—Epirubicin—testicular cancer	1.85e-05	0.000159	CcSEcCtD
Gemcitabine—Vomiting—Doxorubicin—testicular cancer	1.83e-05	0.000157	CcSEcCtD
Gemcitabine—Rash—Doxorubicin—testicular cancer	1.82e-05	0.000156	CcSEcCtD
Gemcitabine—Dermatitis—Doxorubicin—testicular cancer	1.81e-05	0.000156	CcSEcCtD
Gemcitabine—Headache—Doxorubicin—testicular cancer	1.8e-05	0.000155	CcSEcCtD
Gemcitabine—Nausea—Doxorubicin—testicular cancer	1.71e-05	0.000147	CcSEcCtD
Gemcitabine—ABCB1—Metabolism—HPGDS—testicular cancer	1.05e-05	0.000324	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—STK11—testicular cancer	7.61e-06	0.000235	CbGpPWpGaD
